Myriad Genetics grants Dale Muzzey 92,632 options

The award vests in full and becomes exercisable on November 6, 2029, subject to Dale Muzzey's continued service through that date.

Available on EDGAR 11/09/2026 - 04:13 PM EST Accepted by SEC EDGAR 11/09/2026 - 04:13 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Myriad Genetics Inc. Chief Scientific Officer Dale Muzzey received a one-time retention award of a non-qualified stock option covering 92,632 common shares. The option has a $5.92 exercise price and vests and becomes exercisable in full on November 6, 2029, subject to continued service through that date. It expires November 6, 2036.

Insider Trade Summary

Grant/Award: 92,632 shares

Grant/Award 1 txn

Insider Muzzey Dale

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Time-Based Stock Option F1, F2	92,632	$0.00	$0.00

Holdings After Transaction: Time-Based Stock Option — 92,632 options (Direct)

Footnotes (2)

1. F1. Represents a one-time non-qualified stock option granted as a retention award under the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan (the "Plan"). The option vests and becomes exercisable in full on November 6, 2029, subject to the Reporting Person's continued service through that date and the terms and conditions of the Plan and the applicable award agreement.
2. F2. The exercise price equals the closing price of the Issuer's common stock on November 6, 2026, the grant date.

Key Figures

Option shares: 92,632 options covering common shares Exercise price: $5.92 per share Full vesting and exercisability date: November 6, 2029 +1 more

4 metrics

Option shares 92,632 options covering common shares One-time retention award to Chief Scientific Officer Dale Muzzey

Exercise price $5.92 per share Option grant

Full vesting and exercisability date November 6, 2029 Subject to continued service through that date

Expiration date November 6, 2036 Option grant

Key Terms

non-qualified stock option, retention award, vests, exercise price, +1 more

5 terms

non-qualified stock option financial

"one-time non-qualified stock option granted as a retention award"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

retention award financial

"granted as a retention award"

vests financial

"The option vests and becomes exercisable in full"

exercise price financial

"The exercise price equals the closing price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Equity Incentive Plan financial

"under the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many MYGN options did Dale Muzzey receive, and what is the exercise price?

Dale Muzzey received a one-time retention award of options covering 92,632 Myriad Genetics common shares, with an exercise price of $5.92 per share. The option vests and becomes exercisable in full on November 6, 2029, subject to his continued service through that date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Muzzey Dale

(Last) (First) (Middle)

322 NORTH 2200 WEST

(Street)

SALT LAKE CITY UTAH 84116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Time-Based Stock Option(1)	$5.92(2)	11/06/2026		A		92,632		11/06/2029	11/06/2036	Common Stock	92,632	$0	92,632	D

Explanation of Responses:

1. Represents a one-time non-qualified stock option granted as a retention award under the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan (the "Plan"). The option vests and becomes exercisable in full on November 6, 2029, subject to the Reporting Person's continued service through that date and the terms and conditions of the Plan and the applicable award agreement.

2. The exercise price equals the closing price of the Issuer's common stock on November 6, 2026, the grant date.

Remarks:

	By: Justin Hunter For: Dale Muzzey	11/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)